Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abrilumab - Amgen/AstraZeneca

Drug Profile

Abrilumab - Amgen/AstraZeneca

Alternative Names: Abrilimumab; AMG-181; Anti-α4β7 integrin monoclonal antibody; MEDI-7183

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Alpha4beta7 integrin antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 10 Apr 2018 AstraZeneca completes a phase II trial for Ulcerative colitis in Japan (SC) (NCT01959165)
  • 10 Apr 2018 Amgen completes a phase II trial for Ulcerative colitis in USA, Canada, Australia, United Kingdom, Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Netherlands, Poland, Norway, Switzerland and Russia (SC) (NCT01694485)
  • 10 Apr 2018 Amgen completes a phase II trial for Crohn's disease in USA, Canada, European Union and Switzerland (NCT01696396)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top